Werewolf Therapeutics (NASDAQ:HOWL) Coverage Initiated by Analysts at JMP Securities

JMP Securities started coverage on shares of Werewolf Therapeutics (NASDAQ:HOWLFree Report) in a report released on Wednesday morning, Marketbeat reports. The brokerage issued a mkt outperform rating and a $12.00 target price on the stock.

Werewolf Therapeutics Trading Down 0.7 %

Shares of NASDAQ:HOWL opened at $6.02 on Wednesday. The firm has a fifty day moving average of $6.24 and a two-hundred day moving average of $4.09. The firm has a market capitalization of $257.28 million, a P/E ratio of -5.79 and a beta of 0.70. Werewolf Therapeutics has a 12-month low of $1.57 and a 12-month high of $8.19. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.29.

Werewolf Therapeutics (NASDAQ:HOWLGet Free Report) last issued its earnings results on Thursday, March 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.10. The company had revenue of $1.50 million during the quarter, compared to analyst estimates of $2.75 million. Werewolf Therapeutics had a negative net margin of 187.37% and a negative return on equity of 32.25%. On average, equities analysts expect that Werewolf Therapeutics will post -1.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of institutional investors have recently modified their holdings of HOWL. Bank of America Corp DE boosted its stake in shares of Werewolf Therapeutics by 43,994.1% during the 4th quarter. Bank of America Corp DE now owns 1,533,592 shares of the company’s stock valued at $3,144,000 after buying an additional 1,530,114 shares during the period. PFM Health Sciences LP lifted its stake in shares of Werewolf Therapeutics by 35.6% in the 4th quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock valued at $13,387,000 after purchasing an additional 909,895 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Werewolf Therapeutics by 63.9% in the 4th quarter. Millennium Management LLC now owns 838,302 shares of the company’s stock valued at $1,719,000 after purchasing an additional 326,694 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Werewolf Therapeutics by 59.5% in the 4th quarter. Vanguard Group Inc. now owns 873,438 shares of the company’s stock valued at $3,371,000 after purchasing an additional 325,787 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC lifted its stake in shares of Werewolf Therapeutics by 345.0% in the 2nd quarter. Schonfeld Strategic Advisors LLC now owns 326,702 shares of the company’s stock valued at $996,000 after purchasing an additional 253,284 shares during the last quarter. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

Featured Stories

Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.